- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07513285
ACX-362E [Ibezapolstat] til oral behandling af tilbagevendende Clostridioides difficile-infektion
En fase 2 interventionel, åben-label, en-armet undersøgelse af oral Ibezapolstat (ACX-362E) til behandling og reduktion af tilbagevendende Clostridioides difficile-infektion hos patienter med multiple tilbagevendende infektioner (IBZ-PATHFINDER)
Single-arm trial to evaluate the safety and efficacy of ACX-362E [ibezapolstat] in patients with recurrent C. difficile infection (CDI).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Phase 2 multicenter, open-label, single-arm study is designed to evaluate the efficacy, safety, and tolerability of ibezapolstat in the treatment and reduction of recurrence of CDI in an adult patient population that has experienced ≥3 episodes of CDI within the past 12 months. Up to 20 participants will be treated with ibezapolstat 450 mg taken with food every 12 hours for 14 days (28 total doses) and followed for Clinical Cure (Day 16), Sustained Clinical Cure (Day 42), rate of CDI recurrence (Up to Week 24), and Extended Clinical Cure (ECC) (Up to Week 24).
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Dee Rodriguez
- E-mail: dee.rodriguez@acurxpharma.com
Studiesteder
-
-
California
-
Sacramento, California, Forenede Stater, 95817
- Ikke rekrutterer endnu
- UC Davis Medical Center
-
-
Connecticut
-
Hamden, Connecticut, Forenede Stater, 06518
- Rekruttering
- Gastroenterolgy Center of Conneticut
-
-
Florida
-
Coral Gables, Florida, Forenede Stater, 33134
- Rekruttering
- Florida International Medical Research
-
Hialeah, Florida, Forenede Stater, 33012
- Rekruttering
- L&A Morales Healthcare, Inc
-
Miami Lakes, Florida, Forenede Stater, 33014
- Rekruttering
- San Marcus Research Clinc, Inc
-
Miami Springs, Florida, Forenede Stater, 33166
- Rekruttering
- Belis Delgado, MD PA
-
-
Georgia
-
Athens, Georgia, Forenede Stater, 30606
- Rekruttering
- Infectious Disease Consultants of Georgia
-
-
Idaho
-
Idaho Falls, Idaho, Forenede Stater, 83404
- Rekruttering
- Snake River Research PLLC
-
-
Illinois
-
Skokie, Illinois, Forenede Stater, 60077
- Rekruttering
- Endevour Health
-
-
Massachusetts
-
Newton, Massachusetts, Forenede Stater, 02462
- Rekruttering
- Newton-Wellesley Hospital
-
Worcester, Massachusetts, Forenede Stater, 01655
- Rekruttering
- University of Massachusetts Memorial Healthcare
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- Ikke rekrutterer endnu
- University of Minnesota
-
-
New York
-
Massapequa, New York, Forenede Stater, 11758
- Rekruttering
- DiGiovanna Institute for Medical Education and Research
-
-
North Carolina
-
Winston-Salem, North Carolina, Forenede Stater, 27103
- Rekruttering
- Gastroenterology Associates of the Piedmont, PA
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267
- Ikke rekrutterer endnu
- University of Cincinnati
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15215
- Rekruttering
- Romano, Pontzer & Associated
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Southern Star Research Institute, LLC
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84115
- Ikke rekrutterer endnu
- University of Utah
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Confirmed diagnosis of CDI as defined by 1) the presence of diarrhea, defined as passage of ≥ 3 UBMs within 24 hours before study Day 1, AND 2) a stool test result positive for the presence of C. difficile free toxins
- Three or more CDI episodes in the past 12 months, including the current episode, with each episode defined as ≥ 3 unformed stools in 24 hours associated with positive C. difficile toxin test.
- At least 1 of the protocol-qualifying prior CDI episodes, not including the current episode, has been treated with oral vancomycin or with fidaxomicin
Exclusion Criteria:
- Severe, complicated, or life-threatening fulminant CDI with evidence of hypotension (systolic blood pressure < 90 mmHg), septic shock, peritoneal signs or ileus, or toxic megacolon
- Received more than 24 hours of dosing with antibiotics for the current CDI episode:
- Received a live biotherapeutic product (LBP) (Rebyota® or Vowst™) within the past 12 weeks
- Received or current use of anti-C. difficile antibodies, eg, IV immunoglobulin [IVIG], bezlotoxumab
- Active inflammatory bowel disease (Crohn's disease, ulcerative colitis) with chronic diarrhea within 12 weeks before Baseline, or with a history of symptoms > 12 weeks before Baseline without evidence of mucosal healing on colonoscopy within the past year.
- Active irritable bowel syndrome with chronic diarrhea in the past 12 weeks.
- Active gastroenteritis because of Salmonella, Shigella, Escherichia coli 0157H7, Yersinia or Campylobacter, other bacteria, a parasite, or a virus within the past 2 weeks
- Major GI surgery (eg, significant bowel resection) within 3 months of enrollment (does not include appendectomy or cholecystectomy).
- Known current history of a severely compromised immune system
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Ibezapolstat
Active investigational antibacterial agent |
Ibezapolstat 450 mg po Q12H x14 days
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Evaluér frekvensen af CDI Klinisk Helbredelse (CC)
Tidsramme: Dag 16
|
Dag 16
|
|
Evaluér raten for Vedvarende Klinisk Helbredelse (SCC)
Tidsramme: Dag 42
|
Dag 42
|
|
Vurder hyppigheden af CDI-recidiv (rCDI)
Tidsramme: Dag 70
|
Dag 70
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Vurder hyppigheden af CDI-recidiv (rCDI)
Tidsramme: Dag 42
|
Dag 42
|
|
|
Vurder tiden til forbedring af diarré under behandlingsperioden
Tidsramme: Dag 16
|
Dag 16
|
|
|
Vurder incidensen af Udvidet Klinisk Helbredelse (ECC)
Tidsramme: Uge 8, 12 og 24
|
Uge 8, 12 og 24
|
|
|
Vurder hyppigheden af CDI-recidiv (rCDI)
Tidsramme: Uge 12 og 24
|
Uge 12 og 24
|
|
|
Assess the effects of ibezapolstat on quantitative changes to the fecal microbiome
Tidsramme: Day 1 to Week 24
|
The Shannon Diversity Index and Inverse Simpson Diversity Index will be used to quantify biodiversity in a community like the gut microbiome, measuring how many different species are present in a community (richness) and how close in numbers different species in the community are to each other (evenness). |
Day 1 to Week 24
|
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Bestem hyppigheden og alvoren af bivirkninger
Tidsramme: Dag 1 til uge 24
|
Dag 1 til uge 24
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):987-994. doi: 10.1093/cid/ciy149.
- Xu WC, Silverman MH, Yu XY, Wright G, Brown N. Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections. Bioorg Med Chem. 2019 Aug 1;27(15):3209-3217. doi: 10.1016/j.bmc.2019.06.017. Epub 2019 Jun 11.
- Garey KW, McPherson J, Dinh AQ, Hu C, Jo J, Wang W, Lancaster CK, Gonzales-Luna AJ, Loveall C, Begum K, Jahangir Alam M, Silverman MH, Hanson BM. Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. Clin Infect Dis. 2022 Sep 30;75(7):1164-1170. doi: 10.1093/cid/ciac096.
- Eubank TA, Jo J, Alam MJ, Begum K, McPherson JK, Le TM, Horvath TD, Haidacher SJ, Poggio EC, Lin R, Yue CS, Ducharme MP, Koudssi G, Mercier J, Alder JD, Silverman MH, Garey KW; Ibezapolstat Phase 2 Investigator Group. Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study. Lancet Microbe. 2025 Aug;6(8):101126. doi: 10.1016/j.lanmic.2025.101126. Epub 2025 Jun 11.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ACX-362E-202
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .